{
    "2021-11-28": [
        [
            {
                "time": "2021-11-28",
                "original_text": "凯莱英子公司获签27.2亿元供货大单",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "子公司",
                        "供货大单",
                        "27.2亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-28",
                "original_text": "深桑达A拟投资数字广东公司；凯莱英子公司签27.2亿元供货大单",
                "features": {
                    "keywords": [
                        "深桑达A",
                        "数字广东",
                        "凯莱英",
                        "子公司",
                        "供货大单",
                        "27.2亿元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "信息技术",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-28",
                "original_text": "凯莱英子公司签订约27.2亿元订单 恒瑞多款新药获批临床",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "子公司",
                        "订单",
                        "27.2亿元",
                        "恒瑞",
                        "新药",
                        "获批临床"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-28",
                "original_text": "凯莱英：签订日常经营重大合同",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "重大合同"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-28",
                "original_text": "凯莱英：子公司签订约27.2亿元新一批供货合同",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "子公司",
                        "供货合同",
                        "27.2亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-28",
                "original_text": "医药行业周报：本周医药板块上涨1.69% 建议关注OMICRON新变异株及医药三大防疫板块",
                "features": {
                    "keywords": [
                        "医药行业",
                        "周报",
                        "医药板块",
                        "上涨",
                        "1.69%",
                        "OMICRON",
                        "变异株",
                        "防疫板块"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}